CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His), FITC-Labeled is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 24.6 kDa and the accession number is Q5QGZ9-2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 μg | 5 days | $ 1,400.00 | |
500 μg | 5 days | $ 3,720.00 | |
1 mg | 5 days | $ 6,210.00 |
Description | CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His), FITC-Labeled is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 24.6 kDa and the accession number is Q5QGZ9-2. |
Species | Human |
Expression System | HEK293 Cells |
Tag | N-His |
Accession Number | Q5QGZ9-2 |
Synonyms | DCAL-2, HECL, CLL-1, CLECSF7, CD371, CLEC12A, PRO34150, MICL, CLECSF11, CD303, DLEC, DCAL2, CLL1 |
Construction | His65-Ala265 |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
Molecular Weight | 24.6 kDa (predicted). Due to glycosylation, the protein migrates to 35-55 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Supplied as 0.22 μm filtered solution in PBS (pH 7.4). |
Stability & Storage |
It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His), FITC-Labeled CD-371 DCAL-2 HECL CLL-1 CLECSF7 CD371 CLEC12A PRO 34150 CD 371 PRO34150 MICL DCAL 2 CLECSF11 CLL 1 CD303 DLEC CD-303 CLECSF-7 CLECSF 11 CLECSF-11 DCAL2 CD 303 CLECSF 7 PRO-34150 CLL1 recombinant recombinant-proteins proteins protein